NCT06160739View on ClinicalTrials.gov

Role of Sirolimus in Treatment of Microcystic , Mixed Lymphatic and Vascular Malformations

RecruitingOBSERVATIONAL
Enrollment

10

Participants

Timeline

Start Date

November 20, 2023

Primary Completion Date

September 1, 2024

Study Completion Date

September 1, 2024

Conditions
Microcystic Lymphatic MalformationCombined Vascular MalformationVascular Malformations
Interventions
DRUG

Sirolimus 1Mg Oral Tablet

patients with Microcystic , Mixed Lymphatic and Vascular Malformations will be given sirolimus 1 mg oral tab for 3-6 months with follow up of lesion size by clinical exam \& ultrasound \& MRI to compare lesion size before \& after use of the drug with observation of potential side effects \& after exclusion of it before use of the drug

Trial Locations (1)

Unknown

RECRUITING

Sohag university Hospital, Sohag

All Listed Sponsors
lead

Sohag University

OTHER